vein as the scaffold, and autologous endothelial and smooth muscle cells differentiated from cultured mesenchymal stem cells obtained from 20 mL of bone marrow, although the graft was narrowed at 1 year after the surgery and the patient required the second application of new graft implantation (Olausson et al., 2012) . Now in EBioMedicine, they describe another clinical application of bioengineered vascular graft using an autologous peripheral whole blood instead of bone marrow cells, although one graft was also explanted 7 months after initial surgery due to the narrowing. It is indeed very challenging for any type of vascular conduit to maintain the good patency in low-flow venous system. In fact, our previous clinical results also demonstrated that 4 out of 25 venous conduits required balloon angioplasty due to narrowing in the long-term periods (Hibino et al., 2010) .
Many readers would be very interested in the histology of explanted tissue in the patient and would like to know the fate of seeded cells. We have experience of using cultured endothelial cells for seeding our graft. It was difficult to maintain high quality-controlled production process in a stable condition, especially for cell expansion of endothelial cells in vitro. Despite the number of preparatory steps needed for the authors' graft, the rewards look small. If the decellularized vein is easily available, I would recommend trying to use bone marrow mononuclear cells expressing a cytokine effect to recruit host-derived endothelial cells and smooth muscle cells onto the vein, so that the time-consuming cell expansion step can be eliminated. In fact, we demonstrated that the seeded mononuclear cells in the vascular grafts were eventually replaced by cells from adjacent vessels, probably via the body's innate healing mechanism, resulting in neovessels of entirely host cell origin (Hibino et al., 2011) .
Finally, I would like to congratulate the authors on this successful, compassionate clinical application in these very difficult patients for whom conventional approaches were not feasible or hazardous.
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